Jean-François Formela is a partner in the life sciences group and focuses on new advances in biology and drug discovery technologies.
Specializing in venture creation, Jean-François spearheaded the AVDC (Atlas Venture Development Corporation) model, from which both Annovation Biopharma, Arteaus Therapeutics (acquired by Eli Lilly and Company, NYSE: LLY), and Ataxion were born. Jean-François was also behind Atlas’ collaboration with Monsanto Company. He serves on the boards of Annovation Biopharma, Ataxion, F-star, and Spero Therapeutics, and is the chairman of Egalet as well as RaNA Therapeutics, which he co-founded.
Jean-François has been involved in the formation of companies such as Adnexus (acquired by BMS), Archemix, ArQule (NASDAQ: ARQL), Cellzome (acquired by GSK), deCODE (NASDAQ: DCGN), Exelixis (NASDAQ: EXEL), MorphoSys (Xetra: MOR.DE), NxStage (NASDAQ: NXTM), and SGX Pharmaceuticals (NASDAQ: SGXP, acquired by Lilly). He was also an investor in CoStim Pharmaceuticals (acquired by Novartis), Achillion (NASDAQ: ACHN) and a board member of Biochem Pharma (NASDAQ: BCHE, acquired by Shire) and Novexel (acquired by AstraZeneca).
Jean-François joined Atlas Venture in 1993 to build the U.S. life sciences franchise. Prior to joining Atlas, Jean-François worked at Schering-Plough, where he directed U.S. Phase IV studies in all therapeutic areas. Before that, he was responsible for the marketing of Intron A, Schering-Plough’s alpha-interferon. Jean-François began his career as a medical doctor and practiced emergency medicine at Necker University Hospital in Paris.
Jean-François is a member of the Massachusetts General Hospital Research Advisory Council and a trustee of the Boston Institute of Contemporary Art.
He received his MD from Paris University School of Medicine, and his MBA from Columbia University.
Jean-François is a wine aficionado and an accomplished windsurfer.